Company intelligence / Profile preview

CHA Biotech

Ownership: Private
Employees: ~14000
Development stage: Commercial

Overview

CHA Biotech has completed Phase 1 clinical trials for CBT101 (immune cell therapy for solid tumors) and received domestic IND approval for hESC-RPE (embryonic) therapy for age-related macular degeneration[1][2][9]

Therapeutic areas: OncologyRare DiseasesOphthalmologyNeurology
Modalities: Cell therapyGene therapyStem cell therapyImmune cell therapy
Industry: Biotech

Drug pipeline

11 assets

CB-AC-02

10 more assets in the full pipeline.

Request access →

Partnerships

Astellas (formerly Ocata Therapeutics)

Beyond the preview

Go deeper on CHA Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHA Biotech.

Explore the full profile